{"id":"W2760849249","doi":"10.1186/s12967-017-1309-2","title":"Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016","year":2017,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"National Center for Advancing Translational Sciences; Society for Immunotherapy of Cancer","keywords":"Atezolizumab; Durvalumab; Nivolumab; Medicine; Immunotherapy; Pembrolizumab; Avelumab; Oncology; Immune checkpoint; Ipilimumab; Targeted therapy; Melanoma; Internal medicine; Cancer; Cancer research; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001943345,0.001504491,0.0007069888,0.0008275089,0.0006713261,0.00285491,0.00101915,0.00360274,0.06214775],"category_scores_gemma":[0.001509961,0.0002764144,0.0009437564,0.0004902962,0.0004143983,0.002172879,0.001901328,0.00419247,0.03668734],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001276104,"about_ca_system_score_gemma":0.001823722,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006459472,"about_ca_topic_score_gemma":0.001381169,"domain_scores_codex":[0.9991565,0.0001459917,0.00005142818,0.0001550351,0.0002851197,0.000205897],"domain_scores_gemma":[0.9987111,0.0001192235,0.00008617213,0.00004199221,0.0003799476,0.0006615449],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001129426,0.00005490154,0.0001044451,0.0003683459,0.00001254499,0.00009248608,0.0000189147,0.00006084574,0.000944137,0.001152655,0.9208285,0.07624949],"study_design_scores_gemma":[0.00002031838,0.00004642915,0.0003607982,0.0001683665,0.000007026124,0.00008849493,0.00001905999,0.00003068314,0.0001860737,0.0005235596,0.9985439,0.000005370496],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.001733411,0.3234436,0.001563497,0.167449,0.4336718,0.0003380576,0.001714579,0.0003629944,0.06972302],"genre_scores_gemma":[0.01102744,0.202313,0.002597878,0.069139,0.2667567,0.0003586615,0.003274462,0.0003072482,0.4442258],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.06214775,"threshold_uncertainty_score":0.2079049,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04251446897132561,"score_gpt":0.344089545070107,"score_spread":0.3015750760987814,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}